An ongoing dialogue on HIV/AIDS, infectious diseases,
November 30th, 2009
WHO HIV Treatment Guidelines Updated
This just in:
WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms.
Which makes eminent sense, of course. Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing world?
In fact, when you consider the higher incidence of TB and invasive bacterial infections in such settings, it could easily be argued — and has been argued — that starting early would net greater survival gains in resource-poor settings than it would here.
Plus, there’s the CIPRAHT001 Study, which proves it.
But there’s more — the new WHO guidelines also urge that countries “phase out” the use of stavudine in favor of less-toxic NRTIs, and that women continue breastfeeding so long as they are also on ART.
Good news all around.
Categories: Health Care, HIV, Patient Care, Policy
Tags: AIDS, antiretroviral therapy, antiretrovirals, ART, guidelines, HIV, hiv treatment, Infectious Diseases, WHO
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “WHO HIV Treatment Guidelines Updated”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
-
From the Blog — Most Recent Articles
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
- Florida Moves to Cut AIDS Drug Assistance Program — and Drops the Most Prescribed HIV Regimen in the Country January 27, 2026
- Rabies Is Terrifying — and the Challenge of Managing a Low Risk of a Dreadful Disease January 21, 2026
- Influenza — So Familiar, Still So Mysterious January 14, 2026
- How the Z-Pak Took Over Outpatient Medicine, Part 2: The Reckoning January 6, 2026
FROM NEJM — Recent Infectious Disease Articles- The Essential Role of States in Protecting Immunization Access January 29, 2026In the face of U.S. federal policy shifts that threaten to destabilize vaccine access and weaken clinical guidance, states can step in and protect their residents.
- Case 4-2026: An 80-Year-Old Woman with Cough and Hypoxemia January 29, 2026An 80-year-old woman was admitted to the hospital because of cough and hypoxemia (oxygen saturation, 83%). CT of the chest showed diffuse ground-glass opacities in both lungs. A diagnosis was made.
- A New Therapeutic Broadcast on Hepatitis D, a Satellite Virus January 22, 2026Hepatitis D virus (HDV) is known as a satellite virus because it requires the hepatitis B virus (HBV) surface antigen (HBsAg) to enter the hepatocytes and to complete its life cycle. HDV is the smallest human pathogen, with a single-stranded RNA genome that is approximately 1.7 kb long. Yet, chronic...
- Pneumocystis jirovecii Pneumonia January 22, 2026A 60-year-old man with recently diagnosed HIV infection presented with a 10-day history of fever, dry cough, and shortness of breath. A CT scan of the chest showed diffuse nodules and ground-glass opacities.
- Case 3-2026: A 58-Year-Old Woman with Diplopia and Fever January 22, 2026A 58-year-old woman was admitted to the hospital 3 weeks after lumbar surgery because of diplopia and fever. Left leg pain and a rash had preceded the fever and diplopia. A diagnosis was made.
- The Essential Role of States in Protecting Immunization Access January 29, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Should the guidelines have suggested initiation at < 500 as is expected in the next iteration of US centered guidelines? Although ARVs are limited in many parts of the world should an individual patient be witheld therapy when there is an accumulation of data suggesting 500 (or higher) may be the tipping point? A conundrum in areas where supplies of ARVs are limited perhaps.
CM,
I guess one way of looking at “start at CD4 350” is “start at CD4 > 350.” I realize it’s not exactly the same thing, but since you can’t predict when or if the CD4 will drop, as a pt approaches this threshold (i.e., between 350 and 500), it’s time to get ready to start.
As you know, DHHS guidelines just out as well.
Paul